Market Overview:

The global endometriosis market size reached US$ 2.26 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 3.13 Billion by 2028, exhibiting a growth rate (CAGR) of 5.40% during 2023-2028. The rising awareness about symptoms and diagnosis, the easy availability of various generic drugs, and the increasing number of clinical trials represent some of the key factors driving the market.

Endometriosis is a medical disorder wherein tissue similar to the lining of the uterus develops outside of the uterine cavity, fallopian tubes, ovaries, vagina, bladder, rectum, and diaphragm. It causes ovarian cysts, superficial lesions, deeper nodules, adhesions, and scar tissue within the body. It is associated with severe, life-impacting pain during the menstrual cycle, sexual intercourse, bowel movements, and urination. It also causes chronic pelvic pain, abdominal bloating, nausea, fatigue, depression, anxiety, and infertility. It is diagnosed through laparoscopy and rectovaginal examination to identify uterosacral and septal nodules. Endometriosis can be treated using hormone therapy, involving injections, nasal sprays and pills, medications, and surgical treatments to reduce pain and prevent infertility.

Endometriosis Market Trends:

The increasing prevalence of endometriosis represents one of the major factors strengthening the market growth around the world. Moreover, thegrowing demand for minimally invasive (MI) surgical procedures is influencing the market positively. In addition, there is a rise in awareness about endometriosis, its symptoms and diagnosis, and the easy availability of the treatment. This, coupled with the increasing consciousness among women about personal health and hygiene, is contributing to the market growth. Apart from this, the growing adoption of health insurance policies that provide financial assistance for endometriosis treatment and minimize healthcare expenses is creating a positive outlook for the market. Furthermore, governments of numerous countries are financing research and development (R&D) activities to identify therapeutic agents. This, along with the increasing number of clinical trials by pharmaceutical companies, is facilitating the market growth. Besides this, the easy availability of various generic drugs for relieving pain associated with endometriosis and the rising inclination towards postoperative pain management and palliative care services offered in numerous countries are propelling the growth of the market. They generally involve nonsteroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen (Motrin) and naproxen (Naprosyn), progestin, and gonadotropin-releasing hormone (GnRH) agonists that are available over the counter (OTC) and by prescription as pills, liquids, gels, and patches. Additionally, significant improvements in the healthcare infrastructure and diagnostic technologies are anticipated to impel the growth of the market in the coming years.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the global endometriosis market, along with forecasts at the global, regional, and country level from 2023-2028. Our report has categorized the market based on type, diagnosis and treatment, and end users.

Type Insights:

• Superficial Peritoneal Lesion
• Endometrioma
• Deeply Infiltrating Endometriosis
• Others
   

The report has also provided a detailed breakup and analysis of the endometriosis market based on the type. This includes superficial peritoneal lesion, endometrioma, deeply infiltrating endometriosis, and others.

Diagnosis and Treatment Insights:

• Diagnosis
  • Ultrasound
  • Pelvic Exam
  • Laparoscopy
  • Magnetic Resonance Imaging (MRI)
  • Hysteroscopy
  • Sonohysterography
• Treatment
  • Hormonal Therapy
  • Pain Management
  • Conservative Surgery
     

A detailed breakup and analysis of the endometriosis market based on the diagnosis and treatment has also been provided in the report. This includes diagnosis (ultrasound, pelvic exam, laparoscopy, magnetic resonance imaging (MRI), hysteroscopy, and sonohysterography) and treatment (hormonal therapy, pain management, and conservative surgery).

End Users Insights:

• Hospitals
• Homecare
• Speciality Centers
• Others
   

A detailed breakup and analysis of the endometriosis market based on the end users has also been provided in the report. This includes hospitals, homecare, specialty centers, and others. According to the report, hospitals accounted for the largest market share.

Regional Insights:

• North America
  • United States
  • Canada
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
• Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
• Latin America
  • Brazil
  • Mexico
  • Others
• Middle East and Africa
   

The report has also provided a comprehensive analysis of all the major regional markets that include North America (the United States and Canada), Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others), Europe (Germany, France, United Kingdom, Italy, Spain, Russia, and others), Latin America (Brazil, Mexico, and others), and the Middle East and Africa. According to the report, North America was the largest market for endometriosis. Some of the factors driving the North America endometriosis market included the growing demand for minimally invasive (MI) surgical procedures, well-established healthcare infrastructure, improved diagnostic technologies, and research and development (R&D) activities for introducing novel therapies, etc.

Competitive Landscape:

The report has also provided a comprehensive analysis of the competitive landscape in the global endometriosis market. Detailed profiles of all major companies have also been provided. Some of the companies covered include Abbott Laboratories, AbbVie Inc., Bayer AG, Debiopharm Group, Gedeon Richter Plc, Kissei Pharmaceutical Co. Ltd., Myovant Sciences GmbH, Sanofi S.A., Teva Pharmaceutical Industries Ltd., etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

Report Coverage:

Key Questions Answered in This Report:

• How has the global endometriosis market performed so far and how will it perform in the coming years?
• What are the drivers, restraints, and opportunities in the global endometriosis market?
• What are the key regional markets?
• Which countries represent the most attractive endometriosis markets?
• What is the breakup of the market based on the type?
• What is the breakup of the market based on the diagnosis and treatment?
• What is the breakup of the market based on the end users?
• What is the competitive structure of the global endometriosis market?
• Who are the key players/companies in the global endometriosis market?
   

Key Benefits for Stakeholders:

• IMARC’s report offers a comprehensive quantitative analysis of various market segments, historical and current market trends, market forecasts, and dynamics of the endometriosis market from 2017-2028.
• The research study provides the latest information on the market drivers, challenges, and opportunities in the global endometriosis market.
• The study maps the leading as well as the fastest growing regional markets. It further enables stakeholders to identify the key country-level markets within each region.
• Porter's five forces analysis assist stakeholders in assessing the impact of new entrants, competitive rivalry, supplier power, buyer power, and the threat of substitution. It helps stakeholders to analyze the level of competition within the endometriosis industry and its attractiveness.
• Competitive landscape allows stakeholders to understand their competitive environment and provides an insight into the current positions of key players in the market.